Trial · NCT02034513
Adverse events130
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 130
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Insulin Degludec (IDeg) | 68 | 454 | 92 |
| other | Nasopharyngitis | Infections and infestations | Insulin Glargine (IGlar) | 61 | 460 | 73 |
| other | Upper respiratory tract infection | Infections and infestations | Insulin Degludec (IDeg) | 29 | 454 | 34 |
| other | Upper respiratory tract infection | Infections and infestations | Insulin Glargine (IGlar) | 39 | 460 | 41 |
| serious | Abdominal pain | Gastrointestinal disorders | Insulin Degludec (IDeg) | 0 | 454 | 0 |
| serious | Abdominal pain | Gastrointestinal disorders | Insulin Glargine (IGlar) | 1 | 460 | 1 |
| serious | Accidental overdose | Injury, poisoning and procedural complications | Insulin Degludec (IDeg) | 2 | 454 | 2 |
| serious | Accidental overdose | Injury, poisoning and procedural complications | Insulin Glargine (IGlar) | 3 | 460 | 3 |
| serious | Acute coronary syndrome | Cardiac disorders | Insulin Degludec (IDeg) | 0 | 454 | 0 |
| serious | Acute coronary syndrome | Cardiac disorders | Insulin Glargine (IGlar) | 1 | 460 | 1 |
| serious | Acute myocardial infarction | Cardiac disorders | Insulin Degludec (IDeg) | 1 | 454 | 1 |
| serious | Acute myocardial infarction | Cardiac disorders | Insulin Glargine (IGlar) | 1 | 460 | 1 |
| serious | Ascites | Gastrointestinal disorders | Insulin Degludec (IDeg) | 0 | 454 | 0 |
| serious | Ascites | Gastrointestinal disorders | Insulin Glargine (IGlar) | 1 | 460 | 1 |
| serious | Bacterial sepsis | Infections and infestations | Insulin Degludec (IDeg) | 1 | 454 | 1 |
| serious | Bacterial sepsis | Infections and infestations | Insulin Glargine (IGlar) | 0 | 460 | 0 |
| serious | Biliary dyskinesia | Hepatobiliary disorders | Insulin Degludec (IDeg) | 1 | 454 | 1 |
| serious | Biliary dyskinesia | Hepatobiliary disorders | Insulin Glargine (IGlar) | 0 | 460 | 0 |
| serious | Breast cancer in situ | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Insulin Degludec (IDeg) | 1 | 454 | 1 |
| serious | Breast cancer in situ | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Insulin Glargine (IGlar) | 0 | 460 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02034513/events